Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -W-
08.05.2017 13:30:00

Bio-Techne To Present At The Bank Of America Merrill Lynch Health Care Conference

MINNEAPOLIS, May 8, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 18, 2017, at 8:40 a.m. PDT. The conference will be held at the Encore at Wynn Hotel in Las Vegas, Nevada.

Chuck Kummeth

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota. The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls for OEM customer and clinical customers. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $499 million in net sales in fiscal 2016 and has approximately 1,700 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.

 

Bio-Techne

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-bank-of-america-merrill-lynch-health-care-conference-300452624.html

SOURCE Bio-Techne Corporation

Analysen zu Bio-Techne Corpmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Bio-Techne Corp 67,50 3,85% Bio-Techne Corp